Cepheid

At the ASCLS Joint Annual Meeting, learn how testing from Cepheid can support the federal lab community with standardized testing for respiratory viruses #HAIs, and #SexualHealth. https://ow.ly/pU7g50SxsBb

Xpert® HCV from Cepheid has received authorization from the FDA. As the first ever CLIA waived test for HCV RNA in the U.S., Xpert HCV can be part of a “test and treat” program that empowers patients and communities to impact health. #MOREaccess, #TheWorldCantWait, #MOREimpact, #HepC, #HepatitisC Learn more: cepheid.com/hcv

The quality you can trust, now in a smaller footprint. Introducing the new space-saving GeneXpert® System with Touchscreen: an advance in workflow efficiency and user experience with a simplified workflow for #LabTesting. Available in four and sixteen module configuration. #GeneXpert, #MolecularDiagnostics Learn more here: https://ow.ly/hpfG50SuYch

Stay Ahead of Influenza-Like Illnesses (ILI). ILIs can result from pathogens like influenza, SARS-CoV-2, and RSV. These illnesses share symptoms like fever (≥ 38.0 °C) and cough, making diagnosis tricky. Rapid detection and accurate differentiation of respiratory viruses are crucial for better prescribing and improved clinical outcomes. A German model showed that this can also reduce healthcare costs. #PublicHealth #RespiratoryIllness #DiagnosticTesting #ILI #Influenza #COVID19 #RSV Want to learn more? Start here: https://ow.ly/ce3R50Stjeo

Group B Streptococcus (GBS) is responsible for an estimated 150,000 preventable infant deaths and stillbirths annually.* This International Group B Strep Awareness Month, learn more about our Blood Virology, Women’s Health, & Sexual Health testing solutions to aid in detecting #GBS. #MolecularDiagnostics *https://ow.ly/yFUV50Steas https://ow.ly/eoN350Stear

Cepheid’s Xpert® HCV receives FDA authorization with CLIA waiver for hepatitis C RNA testing at the point of care. Transform your diagnostic pathway today with onsite, same-day results you can trust. #MOREtrust, #TheWorldCantWait, #HepC, #HepatitisC Learn more: cepheid.com/hcv

Breaking News! Cepheid receives FDA authorization for the first-ever CLIA waived hepatitis C RNA test in the U.S. The Xpert® HCV test enables detection of HCV and facilitates timely linkage to care within a single clinic visit. #MOREtrust, #TheWorldCantWait, #MOREimpact, #HepC, #HepatitisC Read all about it: https://lnkd.in/eSBmXt_R Learn more about Xpert HCV at Cepheid.com/hcv

Take our poll!

2.4 million people in the US are estimated to be living with hepatitis C and more than half of the people with HCV do not know that they have the virus. If left untreated, hepatitis C can often lead to very serious diseases, such as liver cancer. The current clinical pathway for detection of hepatitis C faces many obstacles, including complex multi-step diagnostic algorithms based on antibody screening and RNA test. This approach is only offered today on a centralized model, which may impact the speed for treatment of patients, the follow ups from diagnosis to treatment and moreover, potentially discouraging at-risk populations from access to testing and care. Today Cepheid received the FDA De Novo authorization and CLIA waiver approval for Xpert® HCV, the only molecular test in the US to detect hepatitis C virus RNA directly from a human capillary whole blood (fingerstick) sample. It is also the first RNA detection technology sensitive enough for active case finding, at the point of care, for hepatitis C. I am excited to share this announcement and very thankful to our +6,000 Team Cepheid associates, who keep leveraging the full potential of molecular biology to find A Better Way to improve patient outcomes and access. Onward and upward Team Cepheid! https://lnkd.in/gA_36uHg

We recognize Sonali Jog, PhD as our monthly Associate Spotlight. Cepheid innovates world-class products, but our people are the reason we succeed. Join us in congratulating Sonali! #BestTeamWins